Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Protagen to Support Pfizer Clinical Drug Development

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
Protagen have signed a collaboration agreement with Pfizer Inc.

Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.

Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Using Biomarkers to Identify Inflammation in Prostate Cancer Patients
Discovery of new biomarkers for chronic inflammation could allow the development of new, more accurate prostate cancer diagnostics.
Wednesday, March 30, 2016
Novel Route to Serum Based Prostate Cancer Diagnostics
Protagen AG has announced the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine.
Thursday, February 11, 2016
Protagen AG Joins RA-MAP Consortium
Protagen AG, a company concerned with the development of advanced diagnostic tools to address some of the most severe autoimmune diseases, has announced that it will join the RA-MAP Consortium.
Thursday, January 21, 2016
Protagen AG Establishes Scientific Advisory Board
Protagen AG, technology leader in the development of novel molecular diagnostics and companion diagnostic concepts for autoimmune diseases, has announced the formation of its Scientific Advisory Board (SAB).
Friday, December 11, 2015
Protagen AG Joins MATURA Consortium
Consortium to support identification of treatment response predictors in Rheumatoid Arthritis (RA).
Wednesday, December 02, 2015
Protagen, Mikrogen Collaborate
Protagen and Mikrogen have agreed on a co-development program for a new diagnostic assay to distinguish between previously infected, seropositive individuals, from newly infected patients with active Lyme disease.
Friday, November 13, 2015
Protagen AG Appoints New Board Members
New members expand expertise in diagnostics commercialization.
Monday, October 05, 2015
Protagen AG Achieves ISO 13485 Certification
The ISO 13485 certification covers the development, production and distribution of in-vitro diagnostics (IVD) for autoimmune diseases.
Wednesday, June 24, 2015
Protagen AG Appoints Bernhard Kirschbaum as New Board Member
Announcement follows recent strategic partnership between Protagen and Qiagen.
Thursday, January 08, 2015
Protagen Successfully Closes New Financing Round
QIAGEN N.V. joins existing investors.
Tuesday, December 16, 2014
Protagen AG and QIAGEN Collaborate
Protagen and QIAGEN partner to offer pharmaceutical companies an innovative companion diagnostic development platform for autoimmune disorders.
Monday, November 17, 2014
Protagen AG Sells Service Business
Protagen AG, Dortmund, divested its 100% subsidiary Protagen Protein Services GmbH (PPS), to Zukunftsfond Heilbronn.
Tuesday, July 02, 2013
Protagen counts on Kairos Expertise in Biobank- Management
Both companies plan long term partnership in which Protagen will profit from the administration and documentation of thousands of patient samples. Protagen will actively present and demonstrate the expertise of Kairos to the market.
Friday, March 30, 2012
Protagen Expands Cooperation with Bayer HealthCare
New collaboration project for the clinical validation of diagnostic biomarkers in Endometriosis.
Thursday, December 08, 2011
Protagen at the European Antibody Congress 2010
Company experts will present the characterization of biotherapeutics with protein microarrays and the latest developments of GMP-compliant protein analysis.
Wednesday, November 03, 2010
Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism and Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Flowering Regulation Mechanism Discovered
Monash researchers have discovered a new mechanism that enables plants to regulate their flowering in response to raised temperatures.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!